ArticleFrontiers in oncology2024

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison.

Wei Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.